Isaac Garcia-murillas

List of Publications by Year
in descending order

41 papers	5,615 citations	159585 30 h-index	265206 42 g-index
42 all docs	42 docs citations	42 times ranked	7752 citing authors

#	Article	IF	Citations
1	Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. Clinical Cancer Research, 2022, 28, 1180-1191.	7.0	30
2	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 309-317.	6.3	60
3	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant inPIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discovery, 2021, 11, 92-107.	9.4	36
4	Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 2021, 12, 2423.	12.8	54
5	Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research, 2020, 26, 608-622.	7.0	71
6	Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancerâ€"Reply. JAMA Oncology, 2020, 6, 439.	7.1	2
7	PIK3CA mutation enrichment and quantitation from blood and tissue. Scientific Reports, 2020, 10, 17082.	3.3	15
8	Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). Frontiers in Oncology, 2020, 10, 505.	2.8	21
9	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptorâ€"Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical Cancer Research, 2020, 26, 5172-5177.	7.0	82
10	Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncology, 2019, 5, 1473.	7.1	237
11	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry, 2019, 65, 1405-1413.	3.2	53
12	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. Clinical Cancer Research, 2019, 25, 6026-6034.	7.0	50
13	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Annals of Oncology, 2019, 30, 945-952.	1.2	103
14	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. British Journal of Cancer, 2019, 120, 247-255.	6.4	13
15	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nature Communications, 2018, 9, 896.	12.8	305
16	Assessing HER2 Amplification in Plasma cfDNA. Methods in Molecular Biology, 2018, 1768, 161-172.	0.9	9
17	Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Annals of Oncology, 2018, 29, 145-153.	1.2	114
18	Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. European Journal of Cancer, 2018, 103, 165-175.	2.8	40

#	Article	IF	Citations
19	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery, 2018, 8, 1390-1403.	9.4	397
20	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. Clinical Cancer Research, 2018, 24, 4763-4770.	7.0	30
21	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Molecular Cancer Therapeutics, 2017, 16, 2022-2034.	4.1	66
22	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. British Journal of Cancer, 2017, 117, 876-883.	6.4	98
23	Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	7.0	194
24	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nature Communications, 2017, 8, 1865.	12.8	108
25	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.9	509
26	Plasma ESR1 Mutations and the Treatment of Estrogen Receptorâ€“Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2961-2968.	1.6	573
27	Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. PLoS ONE, 2016, 11, e0165023.	2.5	29
28	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE, 2015, 10, e0139074.	2.5	50
29	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clinical Cancer Research, 2015, 21, 4586-4596.	7.0	171
30	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 2015, 7, 302ra133.	12.4	889
31	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science Translational Medicine, 2015, 7, 313ra182.	12.4	460
32	An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene, 2014, 33, 2478-2486.	5.9	30
33	Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Research, 2014, 16, R68.	5.0	26
34	The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of Pathology, 2013, 231, 301-310.	4.5	42
35	Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR. Clinical Cancer Research, 2013, 19, 3276-3284.	7.0	157
36	Determination of HER2 Amplification Status on Tumour DNA by Digital PCR. PLoS ONE, 2013, 8, e83409.	2.5	33

#	Article	IF	Citations
37	Cellular apoptosis susceptibility (chromosome segregation 1â€like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. Journal of Pathology, 2012, 228, 471-481.	4.5	33
38	Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1. Cancer Discovery, 2012, 2, 524-539.	9.4	261
39	Rhabdomere biogenesis in Drosophila photoreceptors is acutely sensitive to phosphatidic acid levels. Journal of Cell Biology, 2009, 185, 129-145.	5.2	67
40	lazaro Encodes a Lipid Phosphate Phosphohydrolase that Regulates Phosphatidylinositol Turnover during Drosophila Phototransduction. Neuron, 2006, 49, 533-546.	8.1	73
41	Functional INAD complexes are required to mediate degeneration in photoreceptors of theDrosophila rdgAmutant. Journal of Cell Science, 2005, 118, 1373-1384.	2.0	22